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AbstrAct
Ewing sarcomas (ES) are highly malignant bone or soft tissue tumors. Genetically, 
ES are defined by balanced chromosomal EWS/ETS translocations, which give rise 
to chimeric proteins (EWS-ETS) that generate an oncogenic transcriptional program 
associated with altered epigenetic marks throughout the genome. By use of an 
inhibitor (JQ1) blocking BET bromodomain binding proteins (BRDs) we strikingly 
observed a strong down-regulation of the predominant EWS-ETS protein EWS-FLI1 
in a dose dependent manner. This was further enhanced by co-treatment with an 
inhibitor of the PI3K pathway. Microarray analysis further revealed JQ1 treatment 
to block a typical ES associated expression program. The effect on this expression 
program was mimicked by RNA interference with BRD3 or BRD4 expression, indicating 
that the EWS-FLI1 mediated expression profile is at least in part mediated via such 
epigenetic readers. Consequently, contact dependent and independent proliferation of 
different ES lines was strongly inhibited. Mechanistically, treatment of ES resulted in 
a partial arrest of the cell cycle as well as induction of apoptosis. Tumor development 
was suppressed dose dependently in a xeno-transplant model in immune deficient 
mice, overall indicating that ES may be susceptible to treatment with epigenetic 
inhibitors blocking BET bromodomain activity and the associated pathognomonic EWS-
ETS transcriptional program.
INtrODUctION
Ewing sarcoma (ES) is a highly malignant bone 
and soft tissue neoplasia of still enigmatic histogenesis 
with a prominent stemness phenotype [1, 2]. Histogenesis 
may be endothelial, neuroectodermal [3-5] or osteo-
chondrogenic [6, 7]. ES are characterized by early 
metastasis into lung and bone tissues. Metastasis is 
commonly haematogenous and related to stemness [1, 4, 
8]. Even though prognosis for ES patients has markedly 
improved with the development of multimodal therapeutic 
approaches, the survival rate of patients with advanced, 
multifocal disease is still associated with fatal outcome 
[9-11]. Especially multifocal bone or bone marrow 
disease and the development of metastases in bones are 
catastrophic events in the clinical course of ES patients 
[9, 12]. Genetically, ES is defined by specific balanced 
chromosomal EWS/ETS translocations which give rise 
to oncogenic chimeric proteins, the most common being 
EWS-FLI1 as a consequence of the t(11;22)(q24;q12) 
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translocation [13-15]. Other contributing somatic 
mutations involved in disease development have only been 
observed at low frequency [16-19].
Thus, cancer in children is not solely a genetic 
disease and can neither be understood nor cured 
presumably without epigenetics. We previously identified 
the histone methyl-transferase Enhancer of Zeste, 
Drosophila, Homolog 2 (EZH2), the enzymatic subunit 
of the polycomb PRC2 complex, to be over-expressed 
and regulated as a downstream event via EWS-FLI1 
in ES. RNA interference of EZH2 suppressed tumor 
development and metastasis in vivo and microarray 
analysis of EZH2 knock down revealed an EZH2-
maintained, undifferentiated, reversible phenotype in ES 
[1]. EZH2 suppression resulted in a generalized loss of 
H3K27me3 as well as increase in H3 acetylation. ChIP-
Chip assays for H3K27me3 verified such genes that had 
specifically lost H3K27me3 upon EZH2 silencing [8], 
suggesting that malignant stemness features are preserved 
via epigenetic mechanisms. Recent results further indicate 
that EWS-ETS proteins not only deregulate components of 
the epigenetic machinery in ES [1], but in addition create 
specific epigenetic marks [20, 21] that might be addressed 
by epigenetic therapy. 
BET proteins (BRD2, BRD3, BRD4, and the testis-
specific BRDT) are bromodomain (BRD) containing 
proteins that belong to the bromo and extraterminal (BET) 
subset of BRD proteins. They are nuclear proteins that 
carry 2 bromodomains and an additional ET domain, and 
are implicated in chromatin interactions [22]. They seem to 
associate with transcription complexes and with acetylated 
chromatin [23]. Specific inhibitors of BET proteins such as 
I-BET151 or JQ1 resulted in displacement of BRDs from 
chromatin and inhibition of transcription at key genes such 
as BCL2, MYC, and CDK6 [23]. Initially it was shown 
that JQ1 could block the growth of a rare, aggressive 
form of human squamous carcinoma with BRD4-NUT 
translocation [24] as well as of MYC transformed 
multiple myeloma [25]. Effectivity of JQ1 and inhibition 
of C-MYC or N-MYC was also demonstrated for AML 
[26] or neuroblastoma [27], respectively. 
In addition to BET inhibitors, also enhanced activity 
of the phosphoinositide 3-kinase (PI3K) pathway has been 
linked to MYC turnover [28] and thereby might potentially 
enhance the activity of BET inhibitors. Indeed, PI3K 
inhibition has been suggested as therapeutic option in ES 
before [29] and recent evidence suggests that the pathway 
can modulate expression of the EWS-FLI1 fusion protein 
itself [30]. By use of the BET bromodomain inhibitor JQ1 
we significantly blocked proliferation and in vivo tumor 
growth of different ES lines and strikingly observed a 
strong down-regulation of the pathognomonic EWS-FLI1 
protein. Subsequent analysis revealed that JQ1 treatment 
blocked an ES specific expression program and enhanced 
apoptosis of treated cell lines. 
rEsULts
JQ1 blocks EWs-FLI1 expression in Es
In a previous microarray analysis we identified the 
proto-oncogene MYC as being persistently up-regulated in 
ES (Supplementary Figure S1). To analyze the relevance of 
its expression, we employed the potent BET bromodomain 
inhibitor JQ1 and the PI3K inhibitor BEZ235 as possible 
pathways regulating MYC expression in ES cells and 
compared their impact to such on mesenchymal stem 
cells (MSCs). None of the analyzed ES cells showed any 
down-regulation of MYC expression after treatment with 
different concentrations of JQ1 (Figure 1A, Top) while in 
contrast MSCs showed an up to 65% down-regulation after 
5μM JQ1 treatment in VH54.2 cells (Figure 1A, Bottom). 
Similarly, also BEZ235 treatment revealed no influence 
on MYC expression in ES (data not shown). Therefore, 
we became curious whether the characteristic oncofusion 
protein EWS-FLI1 is involved in MYC regulation and 
analyzed its expression upon treatment (Figure 1B and 
Supplementary Figure S2A). Surprisingly, expression of 
EWS-FLI1 was reduced after either just JQ1 treatment 
or combined JQ1 and BEZ235 treatment, which was 
also confirmed at protein level (Figure 1C). Furthermore, 
PARP1 and caspase 7 cleavage (Figure 1C) increased after 
24 as well as 48 hours JQ1 or combined JQ1 and BEZ235 
treatment, indicating induction of apoptosis of ES cells 
especially after JQ1 and combination treatment.
JQ1 down-regulates an ES specific expression 
profile
To clarify to which extent JQ1 influences gene 
expression in ES cells, we carried out microarray 
analyses on JQ1 treated A673 and TC-71 cells. Analysis 
of differentially expressed genes using volcano plots 
indicated 720 and 405 genes significantly up- and 
down-regulated upon treatment in TC-71 and A673, 
respectively (P-value < 0.01; Figure 2A). Comparison of 
expression data between both cell lines at a fold change 
± 1.5 by Venn analysis (http://bioinformatics.psb.ugent.
be/webtools/Venn/) revealed 811 shared, differentially 
expressed genes (Figure 2B). Further, a heat map of 
244 differentially expressed genes in both cell lines 
(fold change > 1.8) is shown (Figure 2C). Most of the 
identified genes were down-regulated after JQ1 treatment 
(188 genes were down-regulated, 57 were up-regulated, 
GSE72673). Subsequent gene set enrichment analysis 
(GSEA) identified a down-regulation of gene sets typical 
for EWS-FLI1 fusion targets as identified by Zhang 
and colleagues [31] as well as those for Ewing sarcoma 
progenitors identified by Riggi et al. [32] (Figure 2D), 
indicating that JQ1 inhibits EWS-FLI1 expression and 
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Figure 1: blockade of bEt bromodomain proteins blocks EWs-FLI1 but not MYc expression. A. Top, MYC expression 
in ES cell lines A673, SK-N-MC and TC-71 and, bottom, in mesenchymal stem cells L87 and VH54.2 after 48hrs JQ1 treatment as 
measured by qRT-PCR. Data are mean ± SEM; t-test. NTC: non-template control. b. Top, different doses of JQ1 inhibit EWS-FLI1 
expression in ES cell lines A673, SK-N-MC or TC-71, respectively. Bottom, relative expression of EWS-FLI1 measured by qRT-PCR in 
A673, SK-N-MC and TC-71 cells after 24hrs treatment with 500nM BEZ235 and 500nM BEZ235 in combination with 2µM JQ1 compared 
to DMSO control. Data are mean ± SEM; t-test. NTC: non-template control. c. Protein level measured by western blot of EWS-FLI1, 
PARP, CASP7 and loading control. Cells were treated for 24 and 48hrs with 500nM BEZ235, 2µM JQ1, 500nM BEZ235 in combination 
with 2µM JQ1 compared to DMSO control in A673, SK-N-MC and TC-71 cells. Shown is a representative experiment (n=3). *P-value < 
0.05; **P-value < 0.005.
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Figure 2: ES expression profile after JQ1 treatment or RNA interference of BRD genes blocks a typical ES associated 
expression program. A. Volcano plot for DMSO against JQ1 treated ES lines, showing the adjusted significance P-value (-log
10
) plotted 
over fold change (log2). Red, genes with a significance P < 0.01. Microarray data with their normalized fluorescent signal intensities were 
used (RMA, see Materials and Methods; GSE72673). Cells were treated with DMSO or JQ1 for 48hrs, collected, and then analyzed. 
b. Shared genes differentially expressed after JQ1 treatment in 2 different ES lines. For a Venn diagram genes ± 1.5 fold differentially 
expressed were selected for the analysis (http://bioinformatics.psb.ugent.be/webtools/Venn/). c. Heat map of 244 genes, 1.8-fold 
differentially expressed in 2 different ES lines A673 and TC-71 are shown. Each column represents 1 individual array. D. GSEA enrichment 
plots of down-regulated genes after JQ1 treatment. GSEA: http://www.broadinstitute.org/gsea/index.jsp E. Verification of microarray data 
by qRT-PCR of selected genes. ES specific genes were significantly down-regulated after JQ1 treatment in different ES cell lines. F. RNA 
interference of BRD3 or BRD4, respectively with specific siRNAs affects the same ES specific genes as after JQ1 treatment. Results of 
qRT-PCRs are shown. Data are mean ± SEM; t-test. NTC: non-template control.
Oncotarget1455www.impactjournals.com/oncotarget
thereby similarly inhibits an ES typical expression profile 
(Supplementary Table S1). Such genes including DKK2, 
EZH2, GPR64, PAPPA, STEAP1, and STK32B were shown 
to be consistently up-regulated and demonstrated to be 
involved in ES pathogenesis [1, 6, 8, 33, 34]. They were 
verified to be down-regulated by JQ1 treatment using qRT-
PCR, overall confirming results of the microarray analysis 
(Figure 2E).
RNA interference of different BRDs by specific 
sirNAs mimics the JQ1 treatment effect in Es
BRD2, BRD3, BRD4 but not BRDT genes are well 
expressed in ES (Supplementary Figure S1). While JQ1 
has been reported to be most specific for BRD4 protein, 
binding to the remaining BRD proteins was also observed, 
although to a lesser extent [24]. Therefore BRD2, 3 or 4 
were transiently down-regulated by specific siRNA in ES 
and their influence on an ES specific expression profile 
was analyzed. While BRD2 knock down did not result in 
any expression changes on such genes (Supplementary 
Figure S2B), BRD3 and BRD4 knock down uniformly 
resulted in a similar down-regulation of ES specific genes 
(Figure 2F) as observed after JQ1 treatment (Figure 2E), 
concluding that BRD3 as well as BRD4 might be the 
essential targets of JQ1 treatment hereby repressing the 
pathognomonic EWS-FLI1 driven expression profile.
JQ1 treatment inhibits proliferation, cell cycle 
progression and promotes apoptosis
Based on these results, we asked whether the 
inhibition of the EWS-FLI1 specific expression profile 
may also affect the growth abilities of ES. Using the 
xCELLigence assay, we compared contact dependent 
growth of different ES lines A673, SK-N-MC and TC-
71 either treated with 2μM JQ1 or just DMSO (Figure 
3A). Neither of the analyzed cells showed a significant 
increase of cell numbers after JQ1 application. Similarly, 
contact independent growth of JQ1 treated A673, SK-
N-MC and TC-71 revealed a strong reduction of colony 
formation (Figure 3B) in methylcellulose assay. We 
subsequently asked whether this reduction of proliferative 
capacity might be due to changes in cell cycle progression. 
Flow cytometry analysis for all 3 cell lines depicted a 
reduction of G2-M phase while an increase in G1 phase 
was observed after JQ1 treatment in SK-N-MC and TC-
71 cells (Figure 3C) as well as an extension of S phase 
in A673 and SK-N-MC cells. BEZ235 treatment more 
consistently increased the G1 phase of all 3 cell lines 
and had no additional effect on the cell cycle when 
combined with JQ1 (Figure 3C). In addition, the caspase 
3 glow assay revealed an increase of apoptosis after JQ1 
treatment in A673 and TC-71 that was further increased 
by combined treatment with BEZ235 in SK-N-MC cells 
(Figure 3D). These results together with the observed 
PARP1 and caspase 7 cleavage (Figure 1C) indicate a 
strong effect of JQ1 on apoptosis induction in ES.
JQ1 reduces tumor growth in vivo in a dose 
dependent manner
As already demonstrated by others [24-27], JQ1 
may also have a therapeutic effect in vivo. Therefore we 
also evaluated the therapeutic suitability of ES cells to JQ1 
treatment in a xenograft mouse model of Rag2-/-γc-/- mice 
by implanting tumor cells s.c. into mice. Starting with 50 
mg/kg body weight every other day by intraperitoneal 
injection of JQ1 or vehicle we observed no growth rate 
reduction on A673 or TC-71 cells, respectively (Figure 
4A). Assuming that this concentration of JQ1 might be 
too low for a pharmaceutically effective supply over two 
days we also tested more frequent doses on TC-71 cells. 
Administration of 50 mg/kg twice daily for a period of 
14 days resulted in an elongated survival of treated mice 
(Figure 4B, Top and 4D). To confirm these results we 
chose SK-N-MC due to its strict dependency on EWS-
FLI1 expression. Mice were treated twice daily with 50 
mg/kg for 23 days revealing a significant growth reduction 
(Figure 4B, bottom) and decreased tumor weight (Figure 
4E). Further, tumors prepared at the end of the experiment 
and analyzed immunohistochemically for caspase 3 
expression revealed an increased apoptosis rate in tumors 
treated with JQ1 (Figure 4C). However, further increase to 
75 mg/kg twice daily was too toxic and resulted in severe 
weight loss and death of some mice (data not shown). 
Overall, both experiments demonstrated a significant 
inhibition of ES growth in vivo at higher JQ1 dosage 
and the potential therapeutic value of BET bromodomain 
inhibitors for the treatment of ES.
DIscUssION
In Ewing sarcoma (ES) the deregulation of 
components of the epigenetic machinery was previously 
demonstrated as an important step for tumor formation [1, 
8]. Furthermore, it was recently shown that EWS-FLI1 
employs divergent chromatin remodeling mechanisms to 
activate or repress transcription [20, 21]. Herein altered 
epigenetic marks were identified that generated specific 
acetyl-lysine moieties on histones and may be targeted by 
epigenetic reader proteins such as BET proteins (BRD2, 
BRD3, BRD4). Interestingly, all three BET proteins are 
well expressed in ES and may be targeted by specific 
inhibitors of BET proteins such as I-BET151 [23] or 
JQ1 [24]. Such treatment resulted in dislodgment of 
BRDs from chromatin in other tumors and inhibition 
of transcription at key genes involved in apoptosis, cell 
cycle regulation and oncogenesis [26, 27], [35] [36]. It 
was demonstrated that JQ1 could block tumor growth and 
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Figure 3: Treatment with JQ1 blocks proliferation, cell cycle progression and induces caspase dependent apoptosis. 
A. Analysis of proliferation of JQ1 treated ES cell lines in comparison to vehicle with xCELLigence. Cellular impedance was measured 
every 4hrs (relative cell index). Data are mean ± SEM (hexaplicates/group); t-test. b. Analysis of anchorage-independent colony formation 
in methylcellulose of ES lines after JQ1 treatment. Top, data are mean ± SEM of 3 independent experiments (duplicates/group); t-test. 
Bottom, macrographs show a representative experiment with A673, SK-N-MC and TC-71. c. Cell cycle progression upon JQ1 and BEZ235 
treatment. Cell cycle analysis after 24 and 48hrs treatment with 500nM BEZ235, 2µM JQ1, 500nM BEZ235 in combination with 2µM 
JQ1 compared to DMSO treated control in A673, SK-N-MC and TC-71 cells. Shown is a representative experiment (n=3). D. Caspase 3/7 
activity measured after 24hrs treatment with 500nM BEZ235, 2µM JQ1, 500nM BEZ235 in combination with 2µM JQ1 in A673, SK-N-
MC and TC-71. Bars represent mean values expressed as relative light unit (RLU) in percentage of DMSO treated control of 6 biological 
replicate analyzed in three technical replicates each (n=3; SE<0.01). ***P-value < 0.0005.
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Figure 4: treatment with JQ1 inhibits Es tumor growth in vivo. Evaluation of the therapeutic potential of JQ1 application. 
Immune deficient Rag2-/-γc-/- mice were injected s.c. with 2x106 ES cells. 5-7 days later these mice received different doses of JQ1 or vehicle 
i.p., respectively. Delay or inhibition of tumor growth was evaluated. A. Mice were either injected with A673 or SK-N-MC cells and 7 days 
later received 50 mg/kg JQ1 or vehicle every other day. Mice with an average tumor size >10 mm in diameter were considered as positive 
and killed. Kaplan–Meier plots of individual experiments with 5 mice per group are shown. b. Mice were injected with tumor cells s.c. and 
5 days later received twice daily doses for 14 to 23 days for TC-71 and SK-N-MC, respectively. Top, survival of TC-71 inoculated mice. 
Bottom, tumor growth after inoculation with SK-N-MC cells. (6 mice/group). c. To analyze intratumoral changes after high dose JQ1 
application tumors were collected upon tumor burden (TC-71) or after 23 days (SK-N-MC). The pictures show clear increased expression 
of cleaved caspase 3 in tumors treated with JQ1. Bar indicates 0.1 mm. D. Variation of tumor growth characteristics analyzed as a function 
of time until tumors reached >1 cm3 size for TC-71 inoculated mice. E. Determined tumor weight of SK-N-MC inoculated mice at the end 
of the experiment. **P-value < 0.005, ***P-value < 0.0005.
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a recurring feature of the consequences of JQ1 / I-BET151 
treatment was inhibition of MYC, N-MYC or FOSL [37] 
expression, respectively in these tumors. 
MYC over-expression is well known in ES. Its level 
of expression seems to be directly regulated via EWS-
FLI1 [38]. By use of JQ1 in different ES cell lines we 
significantly blocked their proliferation and strikingly 
observed a strong down-regulation of the pathognomonic 
EWS-FLI1 protein. We saw no inhibition of MYC 
expression in ES lines whereas its inhibition was readily 
observed in MSC.
JQ1 treatment suppressed a number of genes typical 
for ES specific expression profiles [5, 8, 32]. For example 
GPR64, a new excellent marker of ES [33], was down-
regulated after JQ1 treatment. Similarly, the expression 
of DKK2, a key player of ES invasiveness and osteolytic 
tumor growth [6], was greatly reduced by JQ1. Further, 
other genes consistently up-regulated and/or shown to 
be involved in ES pathogenesis such as EZH2, PAPPA, 
STEAP1, and STK32B [1, 8, 34] were uniformly inhibited 
by JQ1.
Consistently fewer genes were found to be up-
regulated after JQ1 treatment and included genes involved 
mainly in pathways for cell maturation, differentiation, 
etc. (GSE72673), confirming that EWS-FLI1 itself is 
abrogating differentiation programs and is the driver of 
the immature phenotype of this disease [1, 29].
Interestingly, the JQ1 treatment effect on this 
expression program of ES lines was mimicked by specific 
siRNA-mediated knock down of BRD3 or BRD4 but not 
BRD2 expression, demonstrating that not only BRD4 is an 
important epigenetic reader protein in ES. Displacement of 
BRD3/4 by specific inhibitors has already been shown in 
MLL-fusion positive leukemia [23]. While BRD3 seems 
to preferentially associate with hyper-acetylated chromatin 
along the entire lengths of transcribed genes [39], BRD4-
binding has also been observed in enhancer regions [40]. 
To what areas of chromatin BET proteins bind in ES has 
to be further investigated. 
JQ1 treatment not only suppressed an ES specific 
expression profile but also blocked contact dependent and 
independent proliferation of different ES lines. This seems 
to be due to a partial G1 arrest and S phase elongation of 
the cell cycle as demonstrated previously [24]. In addition, 
induction of apoptosis as demonstrated by PARP1-, 
CASP7-cleavage and increased CASP3 activity seems to 
significantly contribute to the reduction of the proliferative 
ability of ES lines. Single or combination treatment with 
the PI3K/mTOR inhibitor BEZ235 [41] did increase 
apoptosis of ES cell lines although single treatment with 
BEZ235 was less effective than JQ1 application. 
However, a number of substances initially also 
demonstrated efficacy in preclinical models such as single 
treatment with ARA-C [42] or anti-IGFR [43] but in phase 
I clinical trials delivered transient [29] or disappointing 
results [44], emphasizing the need to combine drugs 
that based on the biology of this tumor may result in 
synergistic growth inhibitory effects.
For example, treatment with BEZ235 clearly 
inhibited EWS-FLI1 expression and in combination with 
JQ1 further increased apoptosis induction indicating that 
combination treatment of JQ1 with PI3K/mTOR inhibition 
should be a promising strategy for future therapy of ES.
Also, combination treatment of JQ1 with substances 
like YK-4-279 that directly binds to EWS-FLI1 and 
inhibits its oncogenic activity [45, 46] via blockade of 
specific protein interaction with factors important for 
mRNA splicing [47] and transcription [45] may result 
in synergistic effects on tumor growth and needs to be 
explored in preclinical models of ES.
Similarly, combination treatment with EZH2 
inhibitors such as GSK126 [48, 49] may further increase 
therapeutic efficacy and due to potential synergistic effects 
decrease JQ1 dose levels required for successful treatment 
of ES.
Here, we at first demonstrated that tumor 
development was dose dependently suppressed by 
intra-peritoneal JQ1 application in a xeno-transplant 
model of ES–bearing immune deficient Rag2-/-γc-/- mice. 
Therapeutic efficacious doses, although high, were within 
the range published previously [24, 27, 35]. Overall, our 
results demonstrate that MYC or EWS-FLI1 mediated 
pathognomonic expression programs may be similarly 
targeted by BET bromodomain inhibition, casting BET 
protein inhibition appropriate as a potential platform for 
future combination therapy of this disease. 
MAtErIALs AND MEtHODs
cell lines
ES lines (SK-N-MC and TC-71), neuroblastoma 
lines (CHP126, MHH-NB11, SHSY5Y and SIMA) were 
obtained from the German Collection of Microorganisms 
and Cell Cultures (DSMZ, Braunschweig, Germany). 
A673 was purchased from ATCC (LGC Standards, 
Teddington, UK). Mesenchymal stem cell lines L87 
an  V54.2 were described previously [33]. Cells were 
maintained in a humidified incubator at 37 °C in 5-8 
% CO2 atmosphere in RPMI 1640 (Life Technologies, 
Carlsbad, CA, USA) containing 10 % heat-inactivated 
fetal bovine serum (Biochrom, Berlin, Germany) and 
100 µg/ml gentamicin (Life Technologies). Cell lines 
were checked routinely for purity (e.g. EWS-FLI1 
translocation product, surface antigen or HLA-phenotype) 
and Mycoplasma contamination.
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rNA interference (rNAi)
For transient RNA interference cells were 
transfected with small interfering RNA (siRNA) as 
described previously [1]. To test transfection efficiency 
and gene silencing RNA was extracted and gene 
expression assessed by quantitative Real Time-PCR. 
siRNA sequences are provided in the Supplementary 
Information.
Quantitative real time-Pcr (qrt-Pcr)
Total RNA was isolated and reverse transcribed 
using the High Capacity cDNA Reverse Transcription 
Kit (Thermo Fisher Scientific AG) according to the 
manufacturer’s instructions. Differential gene expression 
was then analyzed by qRT-PCR using TaqMan Universal 
PCR Master Mix and fluorescence detection with Step 
One Plus Real-Time PCR or ABI 7900 instrument 
(Thermo Fisher Scientific AG) as described previously [1, 
33]. Gene expression was normalized to glyceraldehyde-
3-phosphate dehydrogenase (GAPDH). All experiments 
were performed at least in duplicate for each cell line. A 
list of used assays is provided in the Supplementary Data. 
NTC: non template control.
Proliferation assay
Cell proliferation was measured with an impedance-
based instrument system (xCELLigence, Roche/ACEA 
Biosciences, Basel, Switzerland) enabling label-free real 
time cell analysis. Briefly, 4 - 10 x 103 cells were seeded 
into 96-wells with 200 µl media containing 10 % FBS 
and allowed to grow up to 150 hours. Cellular impedance 
was measured periodically every 4 hours and 2μM JQ1 or 
DMSO was added. 
Colony forming assay
Cells were seeded in duplicate into a 35 mm plate at 
a density of 5 x 103 cells per 1.5 ml methylcellulose-based 
media (R&D Systems, Minneapolis, MN, USA) according 
to the manufacturer’s instructions and cultured for 10-14 
days at 37 °C / 5 % CO2 in a humidified atmosphere. 2μM 
JQ1 or DMSO was added 
Immunoblotting
5 x 105 A673, SK-N-MC or TC-71 cells were treated 
with 500nM BEZ235, 2µM JQ1, 1µM JQ1, 500nM 
BEZ235 in combination with 2µM JQ1 or DMSO as 
controls, washed twice with PBS and harvested in lysis 
buffer containing 50mM NaH2PO4 (pH 7.5), 150mM 
NaCl, 1% Triton X-100, 1mM Na3OV4, 5mM Na-
pyrophosphate, 40nM NaF, 1mM EGTA supplemented 
with protease inhibitor cocktail (Complete + 1mM 
EDTA, Roche Diagnostics AG). Protein concentration 
was determined by BCA (Thermo Fisher Scientific AG). 
10–30µg of protein extract was resolved on 4-12% SDS-
PAGE and transferred onto nitrocellulose membrane 
(Thermo Fisher Scientific AG). Primary antibodies 
were used as follows: anti-FLI1 monoclonal antibody 
(MyBioSource LLC, San Diego, USA), anti-PARP 
rabbit polyclonal antibody (Cell Signaling Technology, 
Danvers, USA), anti-Caspase7 antibody (Cell Signaling) 
and loading control (anti-β-tubulin (Sigma-Aldrich, 
St. Louis, USA) or GAPDH (Cell Signaling)). After 
incubation with the appropriate secondary peroxidase-
conjugated antibodies, detection was performed with the 
ECL chemiluminescence reagent (Amersham Biosciences, 
Little Chalfont, UK).
FACS analysis
Treated cells were washed with PBS, collected, 
fixed with 70% Ethanol for 2hrs on ice and stained with 
PI solution- for 1hr at room temperature- 20 µg/ml PI 
(Sigma-Aldrich), PBS, 0.1% TritonX, 200 µg/ml RNAse A 
for measurement with a FACS Canto. Data were analyzed 
using Flow Jo program (Flow Jo LLC., Ashland, OR, 
USA).
Casp3/7 assay
4 x 103 A673, SK-N-MC or TC-71 cells, were plated 
in a 384-well plate previously coated with 0.2% gelatin. 
After 24hrs, cells were treated with 500nM BEZ235, 
2µM JQ1, 500nM BEZ235 in combination with 2µM 
JQ1 or DMSO as controls. 24hrs after treatment Caspase 
3/7 reagent (Promega AG) was added in each well and 
luminescence was measured. 
Microarray analysis
Biotinylated target cRNA was prepared as 
previously described [1]. A detailed protocol is available 
at www.affymetrix.com. Samples were hybridized to 
Affymetrix Human Gene 1.0 ST microarrays and analyzed 
by Affymetrix software expression console, version 1.1. 
For the data analysis, robust multichip average (RMA) 
normalization was performed, including background 
correlation, quantile normalization, and median polish 
summary method. Probes of the normal body map (NBA) 
included tissues of normal PBMC, bone marrow, spleen, 
thymus, stomach (2), small intestine, colon w/ mucosa, 
heart, liver, lung, skeletal muscle, brain (whole), brain 
cerebellum, spinal cord, trachea, salivary gland, prostate, 
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testis, uterus, fetal brain, and fetal liver. Array data were 
submitted at GEO (GSE45544).
Animal model
Immune deficient Rag2-/-γc-/- mice on a BALB/c 
background were obtained from the Central Institute for 
Experimental Animals (Kawasaki, Japan) and maintained 
in our animal facility under pathogen-free conditions in 
accordance with the institutional guidelines and approval 
by local authorities (Regierung von Oberbayern). 
Experiments were performed in 6-20 week old mice. 
In vivo experiments
To examine in vivo tumorigenicity, 2-3 x 106 ES 
cells were injected subcutaneously into the inguinal 
region of immune deficient Rag2-/-γc-/- mice. JQ1 was 
handled and dissolved as recommended by the Bradner 
lab and administered at 50 mg/kg body weight intra 
peritoneal either twice daily or every other day. Mice were 
monitored daily and tumor xenografts were measured with 
digital calipers, and tumor volume was calculated as (L x 
W2) / 2, where L is length and W is width. Experimental 
endpoints were determined by completion of treatment 
or attainment of tumor burden exceeding 1 cm3. Upon 
reaching endpoints, mice were humanely euthanized and 
tumors excised and characterized. 
Histology
Histological analysis of tumor specimens was 
performed in a minimum of 5 mice per group. Tissues 
organs were fixed in phosphate buffered 4% formaldehyde 
and paraffin embedded. 3-5µm thick sections from all 
tissues were stained with hematoxylin and eosin (H&E). 
Apoptosis was evaluated by immunohistochemistry (IHC) 
using cleaved Caspase 3 (Cell Signaling) as primary 
antibody. The IHC was performed using the streptavidin–
peroxidase method with an automated immunostainer 
(DiscoveryXT; Roche, Penzberg, Germany), All sections 
were reviewed and interpreted by two pathologists.
Statistical analyses
Data are mean ± SEM as indicated. Differences 
were analyzed by unpaired two-tailed student’s t-test as 
indicated using Excel (Microsoft, Redmond, WA, USA) 
or Prism 5 (GraphPad Software, San Diego, CA, USA); 
P-values < 0.05 were considered statistically significant 
(*p < 0.05; **p < 0.005; ***p < 0.0005). Volcano plots 
were drawn using R, a free software environment available 
at http://www.r-project.org/. 
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